MarketLens

Is Roche's Fenebrutinib a Game Changer for Multiple Sclerosis Treatment

7 months ago

SHARE THIS ON:

Is Roche's Fenebrutinib a Game Changer for Multiple Sclerosis Treatment

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Is UCB's $2.2 Billion Bet on Candid Therapeutics a Game Changer for Autoimmune Treatment

Is UCB's $2.2 Billion Bet on Candid Therapeutics a Game Changer for Autoimmune Treatment

5 months ago

Is Bristol Myers Squibb's New Multiple Myeloma Drug a Game Changer

Is Bristol Myers Squibb's New Multiple Myeloma Drug a Game Changer

8 months ago

Is Netflix's Strategic Pivot a Game Changer for Investors

Is Netflix's Strategic Pivot a Game Changer for Investors

7 months ago

A Game Changer for Schizophrenia Treatment? Teva and Medincell's Olanzapine LAI Accepted by FDA

A Game Changer for Schizophrenia Treatment? Teva and Medincell's Olanzapine LAI Accepted by FDA

7 months ago

Category

Top Featured Pro Only Stock Analysis Investment Ideas ETFs Crypto

You may also like

Stock News•2 weeks ago

Genentech's Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both Relapsing and Primary Progressive Multiple Sclerosis

Genentech's fenebrutinib received FDA filing acceptance for both relapsing and primary progressive multiple sclerosis, making it the first BTK inhibitor accepted for both forms. The FDA's acceptance a...

Stock News•2 weeks ago

Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?

Biogen's growth products, including Skyclarys and Zurzuvae, now outpace its legacy multiple sclerosis portfolio, shifting the revenue mix. The transition reduces reliance on declining MS drugs but con...

Stock News•1 months ago

Immunic: Potent Under-The-Radar MS Lineup Set For A Rerating

Immunic's vidofludimus calcium (IMU-838) is advancing in late-stage trials for relapsing and progressive multiple sclerosis, targeting a market projected at ~$22 billion in 2026 revenues. Its oral dos...

Breaking News

Convertible Bonds

Debt/Share Issuance

Dividend Announcements

Forward Guidance Revisions

Guidance Updates

Valuation Multiples

Featured Articles

DoorDash (DASH): Founder Selling Signals Liquidity, Not Lack of Confidence Amid Robust Growth

DoorDash (DASH): Founder Selling Signals Liquidity, Not Lack of Confidence Amid Robust Growth

2 months ago

Sea Limited's Growth Momentum Outweighs COO's Programmed De-risking

Sea Limited's Growth Momentum Outweighs COO's Programmed De-risking

2 months ago

Arista Networks' AI Momentum Encounters Founder's Planned Profit-Taking

Arista Networks' AI Momentum Encounters Founder's Planned Profit-Taking

2 months ago

Top Headlines

Stock News•57 minutes ago

Amazon's new Bee AI devices have a bystander problem, says former AWS security engineer

Stock News•1 hour ago

Here's Why ServiceNow (NOW) Fell More Than Broader Market

Stock News•1 hour ago

Salesforce (CRM) Suffers a Larger Drop Than the General Market: Key Insights

Stock News•1 hour ago

1 Obvious Metric That Makes Nvidia a Top Stock to Buy Now

Stock News•1 hour ago

S&P 500 Snapshot: Stocks Slide Nearly 2% for the Week